Asked by: Lord Taylor of Warwick (Non-affiliated - Life peer)
Question to the Department for Science, Innovation & Technology:
To ask His Majesty's Government what assessment they have made of the extent to which the AI-Driven Innovation Centre, announced at the World Economic Forum in January, aligns with the UK’s artificial intelligence strategy and wider policy objectives.
Answered by Baroness Lloyd of Effra - Baroness in Waiting (HM Household) (Whip)
AI is already transforming how we make products, discover new medicines and power innovation in areas like financial services. Scaling up adoption across these sectors and beyond is essential to boosting productivity, creating good jobs and driving Britain’s economic renewal.
The new Centre for AI-Driven Innovation will play a central role in delivering the UK’s ambitions for AI—bringing together world-leading research, industry expertise and international partners to turn ideas into real-world impact. By accelerating progress on the AI Opportunities Action Plan, it will help the UK go further and faster in strengthening its position as a global leader and hub for innovation in the age of AI. Innovation will play a central role in delivering the UK’s ambitions for AI—bringing together world‑leading research, industry expertise and international partners to turn ideas into real‑world impact.
The Centre’s focus on driving responsible AI adoption across key sectors—including advanced manufacturing, life sciences and professional services—directly supports the Government’s aims to boost productivity, enhance technological leadership and promote the safe, trustworthy deployment of AI across the economy.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the uptake of generic and biosimilar medicines to meet the objectives set out in the Government’s Life Sciences Sector Plan.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom is a global leader in adopting biosimilar and generic medicines, which deliver major National Health Service savings and expand patient access to effective treatments sooner.
We are working with the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE), and NHS England to understand forthcoming biosimilars and to ensure they reach the frontline efficiently. Through NHS England’s Best Value Biologicals Framework, clinicians start patients on the most cost‑effective biologics where appropriate, and switches are made swiftly and safely. This has already delivered £1.2 billion in savings over the past three years.
As set out in the 10‑Year Health Plan and Life Sciences Sector Plan, we are streamlining regulation, improving procurement, and reducing variation in uptake. NICE’s whole‑lifecycle approach ensures clinical pathways are regularly reviewed so that patients benefit as soon as cost‑effective generics and biosimilars become available, as seen in recent cancer treatments. These actions support timely access to effective off‑patent medicines and a sustainable, competitive market for the NHS.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Government plans to reinstate the Life Sciences Council.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. The sector is forecast to grow by £41 billion and create 100,000 jobs by 2030, supporting our ambition to lead Europe in life sciences by 2030.
The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what consideration has been given to the role of the generic and biosimilar medicines sector in shaping life sciences policy, in the context of it supplying around 85% of NHS prescription drugs by volume.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of reinstating the Life Sciences Council with representation from the generic and biosimilar medicines industry.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when the Government plans to establish a task and finish group to oversee delivery of the Life Sciences Sector Plan as it relates to generic and biosimilar medicines.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that increased medicine prices do not have an adverse impact on NHS activity.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector to increase access to life-changing medicines without taking essential funding from our frontline NHS services.
We will always prioritise the needs of NHS patients and at the Spending Review we delivered record real terms increase for day-to-day spending for the NHS in England up to April 2029.
This deal will be funded by allocations made at the Spending Review, where front line services will remain protected through the record funding secured. Future year funding will be settled at the next Spending Review.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of Health Innovation Network Impact Report 2024–25, published on 18 September 2025, in relation to the use of point-of-care diagnostic testing technologies for cardiovascular disease prevention in the NHS.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government welcomes the Health Innovation Network (HIN) Impact Report 2024/25, and the network's focus on cardiovascular disease as a strategic priority. We recognise the significant impact of the HINs in driving innovation into the National Health Service, benefitting 4.9 million patients and leveraging £3 billion of investment since 2018. This is why the Government’s 10-Year Health Plan and the Life Sciences Sector Plan make explicit commitments to continue funding and empowering them.
As set out in the 10-Year Health Plan, to accelerate progress on the ambition to reduce premature deaths from heart disease and stroke by 25% within a decade, we will publish a new cardiovascular disease modern service framework later this year.
Asked by: Julia Lopez (Conservative - Hornchurch and Upminster)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what discussions she has had with the life sciences sector on the application of VAT on medicines supplied free-of-charge via EAMS and other compassionate access schemes.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Secretary of State for Science, Innovation and Technology regularly engages with representatives of the life sciences sector. The issue of the application of VAT on medicines supplied free-of-charge via Early Access to Medicines Scheme (EAMS) and other compassionate access schemes has been raised with Ministers.
Application of VAT is determined on a case-by-case basis depending on the nature of the supply. This includes medicines or treatments provided for free under the EAMS.
In certain circumstances the giving of goods away for free can be outside the scope of VAT. Where the supply is within the scope of VAT a relief may apply, meaning the supply can be made VAT free.
Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Department for Science, Innovation and Technology about the potential merits of a respiratory Modern Service Framework to improve the UK’s life sciences ecosystem by scaling up the adoption of new medicines and innovations for lung conditions.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government will consider the long-term conditions for future waves of modern service frameworks (MSFs), including for respiratory conditions. The criteria for determining other conditions for future MSFs will be based on where there is potential for rapid and significant improvements in quality of care and productivity. After the initial wave of MSFs is complete, the National Quality Board will determine the conditions to prioritise for new MSFs as part of its work programme. There has not, therefore, been a specific assessment made in relation to winter pressures.
NHS England and the Department of Health and Social Care are working with the Department for Science, Innovation and Technology to explore innovation and policy prioritisation in respiratory health, including the cross‑Government alignment that may be required.
Data is available for emergency Finished Admission Episodes (FAEs) where there was a primary diagnosis of 'respiratory conditions’. The following table shows the emergency FAEs where there was a primary diagnosis of 'respiratory conditions’ in Mid Sussex and for England overall, in English National Health Service hospitals and for English NHS commissioned activity in the independent sector, for 2024/25 and 2025/26:
Westminster Parliamentary Constituency of Residence | 2024/25 (August 2024 to March 2025) | 2025/26 (April 2025 to November 2025) |
Mid Sussex | 885 | 555 |
England | 608,449 | 423,588 |
Source: Hospital Episode Statistics, NHS England.
Note: the data for 2025/26 is provisional.
The Government has committed to delivering three big shifts that our NHS needs to be fit for the future: from hospital to community; from analogue to digital; and from sickness to prevention. All of these are relevant to improving respiratory health in all parts of the country.
Through the community diagnostic centres, we are building capacity for respiratory testing and enabling people to get tested closer to home. Earlier diagnosis of conditions will help prevent deterioration and improve survival rates. We are also focused on expanding capacity and improving quality in pulmonary rehabilitation delivery to support patients living with respiratory conditions. We are also taking action to reduce the causes of respiratory conditions such as enabling a smoke free generation and cross Government action to improve air quality.